share_log

Allarity Therapeutics | SCHEDULE 13G: Others

Allarity Therapeutics | SCHEDULE 13G: Others

Allarity Therapeutics | SCHEDULE 13G:其他
美股SEC公告 ·  2024/08/30 06:01

Moomoo AI 已提取核心信息

Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.
Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.
Olmsted投资有限责任公司于2024年8月19日向美国证券交易委员会提交了13G表,显示其在Allarity Therapeutics,Inc.中持有重要的所有权。这家总部位于犹他州的投资公司报告称,拥有10,000股Allarity的A系列可转换可赎回优先股,占该类别股份的28.6%。这份申报文件是对持有公司股份超过5%的各方的要求,规定Olmsted投资有限责任公司对这些股份拥有唯一的投票和支配权。Allarity Therapeutics的主要执行办公室地址列为马萨诸塞州波士顿市学校街24号2楼,邮编02108。Olmsted投资有限责任公司已经证明,收购这些股份不是为了改变或影响Allarity Therapeutics的控制权,也与具有此目的或效果的任何交易无关。
Olmsted投资有限责任公司于2024年8月19日向美国证券交易委员会提交了13G表,显示其在Allarity Therapeutics,Inc.中持有重要的所有权。这家总部位于犹他州的投资公司报告称,拥有10,000股Allarity的A系列可转换可赎回优先股,占该类别股份的28.6%。这份申报文件是对持有公司股份超过5%的各方的要求,规定Olmsted投资有限责任公司对这些股份拥有唯一的投票和支配权。Allarity Therapeutics的主要执行办公室地址列为马萨诸塞州波士顿市学校街24号2楼,邮编02108。Olmsted投资有限责任公司已经证明,收购这些股份不是为了改变或影响Allarity Therapeutics的控制权,也与具有此目的或效果的任何交易无关。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息